VKT-17-P4-23
Based on 1 Customer Validation
VKT-17-P4-23 is a blood-brain barrier-permeable DksA inhibitor. DksA is a highly conserved transcriptional regulator in Gram-negative bacteria, with a Kd of 124 μM. Through the DksA-regulated, SPI-2-dependent survival pathway, VKT-17-P4-23 exhibits antibacterial activity against both planktonic and intracellular pathogens such as Salmonella, and also effectively combats persistent bacteria that are difficult to eliminate. VKT-17-P4-23 can be used in studies of Salmonella infection.
For research use only. We do not sell to patients.
- CAS No.: 2411865-57-9
- Formula: C13H16N4O
- Molecular Weight:244.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
VKT-17-P4-23 (16 μg/mL; 20 h) inhibits growth of S. Typhimurium ATCC strain 14028s in EG minimal medium with an MIC of 16 μg/mL[1].
VKT-17-P4-23 (≥4 μg/mL; 20 h) inhibits growth of intracellular S. Typhimurium in J774 macrophage-like cells in a dose-dependent manner, with significant activity at concentrations ≥4 μg/mL[1].
VKT-17-P4-23 (16 μg/mL; 20 h) significantly reduces survival of in vitro-selected persistent S. Typhimurium cells exposed to DNA synthesis inhibitors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
VKT-17-P4-23 (10 mg/kg; i.p.; every 12 hours; 12 hours pre-infection plus 3 total post-infection doses) significantly reduces Salmonella burden in systemic murine infection, eliminates liver histopathological lesions, and normalizes plasma liver enzyme levels[1].
VKT-17-P4-23 (10 mg/kg; i.p.; every 12 hours; 12 hours pre-infection plus 3 total post-infection doses) significantly reduces Salmonella burden in both gastrointestinal and systemic tissues during oral murine salmonellosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (6 to 8 weeks old, 5 males, 5 females, intraperitoneal inoculation with Salmonella enterica serovar Typhimurium)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 12 hours; 12 hours pre-infection plus 3 total post-infection doses
-
Result:Reduced Salmonella burdens in livers, spleens, and cecal contents significantly compared to vehicle controls.
Eliminated measurable histopathological liver lesions, reducing inflammatory foci counts to near zero.
Normalized plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels to basal levels matching uninfected naïve mice.
-
Animal Model:C57BL/6 (6 to 8 weeks old, streptomycin pretreatment, oral inoculation with Salmonella enterica serovar Typhimurium)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 12 hours; 12 hours pre-infection plus 3 total post-infection doses
-
Result:Reduced Salmonella burdens in cecal contents significantly compared to vehicle controls.
Reduced Salmonella burdens in Peyer’s patches significantly compared to vehicle controls.
Reduced Salmonella burdens in mesenteric lymph nodes significantly compared to vehicle controls.
Reduced Salmonella burdens in livers significantly compared to vehicle controls.
Chemical Information
-
CAS No. 2411865-57-9
-
Appearance Powder
-
Molecular Weight 244.29
-
Formula C13H16N4O
-
SMILES
O=C(C1=NNC=N1)NCCCCC2=CC=CC=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz